BR112022020486A2 - Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso - Google Patents
Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de usoInfo
- Publication number
- BR112022020486A2 BR112022020486A2 BR112022020486A BR112022020486A BR112022020486A2 BR 112022020486 A2 BR112022020486 A2 BR 112022020486A2 BR 112022020486 A BR112022020486 A BR 112022020486A BR 112022020486 A BR112022020486 A BR 112022020486A BR 112022020486 A2 BR112022020486 A2 BR 112022020486A2
- Authority
- BR
- Brazil
- Prior art keywords
- covid
- fusion proteins
- cov
- sars
- patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
IMUNOTERAPIA ESPECÍFICA DE ANTÍGENO PARA PROTEÍNAS DE FUSÃO DE COVID-19 E MÉTODOS DE USO. A presente descrição provê proteínas de fusão recombinantemente fabricadas compreendendo um fragmento do Domínio de Ligação de Receptor do SARS-CoV-2 (SARS-CoV-2-RBD) ou um análogo do mesmo ligado a um fragmento Fc humano para o uso em relação ao Novo Coronavírus 2019 (COVID-19). As modalidades incluem a administração das proteínas de fusão aos pacientes que se recuperaram de COVID-19 como uma vacinação de reforço, aos pacientes ingênuos em anticorpo para produzir anticorpos para o vírus SARS-CoV-2 para permitir que os pacientes de tornem doadores de plasma convalescente, aos pacientes que foram infectados pelo vírus SARS-CoV-2 e contraíram COVID-19 de modo a limitar o âmbito da infecção e melhorar a doença e como uma vacina profilática contra o COVID-19. As proteínas de fusão Fc exemplares e formulações farmacêuticas de proteínas de fusão Fc exemplares são providas, além de métodos de uso e preparação.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063008503P | 2020-04-10 | 2020-04-10 | |
US202063008497P | 2020-04-10 | 2020-04-10 | |
US202063008515P | 2020-04-10 | 2020-04-10 | |
US202063008509P | 2020-04-10 | 2020-04-10 | |
US202063041582P | 2020-06-19 | 2020-06-19 | |
US202063041584P | 2020-06-19 | 2020-06-19 | |
US202063041579P | 2020-06-19 | 2020-06-19 | |
US202063041574P | 2020-06-19 | 2020-06-19 | |
US202063048939P | 2020-07-07 | 2020-07-07 | |
US202063068894P | 2020-08-21 | 2020-08-21 | |
US202063068843P | 2020-08-21 | 2020-08-21 | |
US202063068775P | 2020-08-21 | 2020-08-21 | |
US202063068805P | 2020-08-21 | 2020-08-21 | |
US202063068911P | 2020-08-21 | 2020-08-21 | |
PCT/US2021/026577 WO2021207599A1 (en) | 2020-04-10 | 2021-04-09 | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020486A2 true BR112022020486A2 (pt) | 2023-01-17 |
Family
ID=75640036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020486A BR112022020486A2 (pt) | 2020-04-10 | 2021-04-09 | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
Country Status (17)
Country | Link |
---|---|
US (3) | US11213581B2 (pt) |
EP (2) | EP4248983A3 (pt) |
JP (1) | JP2023522597A (pt) |
KR (1) | KR20220167317A (pt) |
CN (1) | CN116096733A (pt) |
AU (2) | AU2021253926B2 (pt) |
BR (1) | BR112022020486A2 (pt) |
CA (1) | CA3146464C (pt) |
DK (1) | DK3972987T3 (pt) |
FI (1) | FI3972987T3 (pt) |
HR (1) | HRP20230990T1 (pt) |
HU (1) | HUE062716T2 (pt) |
IL (1) | IL297064A (pt) |
LT (1) | LT3972987T (pt) |
SI (1) | SI3972987T1 (pt) |
WO (1) | WO2021207599A1 (pt) |
ZA (1) | ZA202210992B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112500498B (zh) * | 2020-02-26 | 2022-09-06 | 四川大学 | 新型冠状病毒疫苗及其制备方法和应用 |
HUE062716T2 (hu) * | 2020-04-10 | 2023-11-28 | Akston Biosciences Corp | Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások |
EP4265272A1 (en) * | 2020-12-16 | 2023-10-25 | Instituto Finlay De Vacunas | Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity |
WO2022133547A1 (en) * | 2020-12-23 | 2022-06-30 | The University Of Melbourne | Coronavirus vaccine |
KR20220109996A (ko) * | 2021-01-29 | 2022-08-05 | (주)셀트리온 | 사스-코로나바이러스-2 융합 단백질 및 이를 포함하는 면역원성 조성물 |
CN114014940B (zh) * | 2021-11-25 | 2022-11-15 | 华兰基因工程有限公司 | 一种2019-nCoV表面蛋白受体结合区融合蛋白制备方法 |
CN113980135B (zh) * | 2021-12-27 | 2022-04-19 | 三优生物医药(上海)有限公司 | 一种结合冠状病毒双特异性抗体的抗药抗体及其制备方法和应用 |
WO2023154402A2 (en) * | 2022-02-09 | 2023-08-17 | University Of Maryland, College Park | Compositions and methods for fcrn-targeted intranasal coronavirus vaccination |
WO2023212579A1 (en) * | 2022-04-25 | 2023-11-02 | Boost Biopharma, Inc. | Recombinant polypeptides containing at least one immunogenic fragment and uses thereof |
WO2024014943A1 (ko) * | 2022-07-12 | 2024-01-18 | 에스케이바이오사이언스 주식회사 | Sars-cov-2 백신 부스터 조성물 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040601A1 (en) | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
WO2007018619A2 (en) * | 2005-07-29 | 2007-02-15 | Amprotein Corporation | Chimeric therapeutic agents |
EP2408470A4 (en) | 2009-03-20 | 2012-08-29 | Smartcells Inc | SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE |
CA2754408A1 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
US8933207B2 (en) | 2010-07-28 | 2015-01-13 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
WO2012015692A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
WO2013074598A1 (en) | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
UA119533C2 (uk) | 2013-02-26 | 2019-07-10 | Ханмі Фарм. Ко., Лтд. | Аналог інсуліну та його застосування |
WO2015080973A1 (en) | 2013-11-26 | 2015-06-04 | Baylor College Of Medicine | A novel sars immunogenic composition |
US10287336B2 (en) | 2014-09-18 | 2019-05-14 | AskGene Pharma, Inc. | Feline erythropoietin receptor agonists |
US10822386B2 (en) | 2014-12-24 | 2020-11-03 | Case Western Reserve University | Insulin analogues with enhanced stability and reduced mitogenicity |
AU2016212707A1 (en) | 2015-01-29 | 2017-08-10 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
WO2016133372A2 (ko) | 2015-02-17 | 2016-08-25 | 한미약품 주식회사 | 지속형 인슐린 또는 이의 아날로그 결합체 |
CN107709355B (zh) | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー/エス | 極性の組換え延長部を有するインスリン |
EP3377520A4 (en) | 2015-11-16 | 2019-11-06 | Ubiprotein, Corp. | METHOD FOR EXTENDING THE HALF-LIFE OF A PROTEIN |
CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
TWI774694B (zh) | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
WO2018107117A1 (en) | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
UY37629A (es) | 2017-03-07 | 2018-10-31 | Univ Case Western Reserve | Análogos de insulina de cadena simple estabilizados por un cuarto puente disulfuro |
JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用igg fc変異体 |
CN112423741A (zh) | 2018-04-16 | 2021-02-26 | 犹他大学研究基金会 | 葡萄糖反应性胰岛素 |
US11696948B2 (en) * | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
SI3892628T1 (sl) | 2018-06-29 | 2023-01-31 | Akston Biosciences Corporation | Ultra dolgo delujoči inzulin-fc-fuzijski proteini in postopki za uporabo |
WO2020069011A1 (en) | 2018-09-25 | 2020-04-02 | Absci, Llc | Protein purification methods |
MA53809A (fr) | 2018-10-05 | 2022-01-12 | Novo Nordisk As | Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) |
US20220002373A1 (en) | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
US20220235111A1 (en) | 2019-05-17 | 2022-07-28 | Case Western Reserve University | Variant Single-Chain Insulin Analogues |
WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
CA3145491A1 (en) | 2019-07-31 | 2021-02-04 | Stacey Lynn Lee | Relaxin analogs and methods of using the same |
WO2021126584A1 (en) | 2019-12-19 | 2021-06-24 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
CN111333704B (zh) * | 2020-02-24 | 2021-01-12 | 军事科学院军事医学研究院微生物流行病研究所 | 新型冠状病毒covid-19疫苗、制备方法及其应用 |
US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
HUE062716T2 (hu) * | 2020-04-10 | 2023-11-28 | Akston Biosciences Corp | Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások |
US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
CN111647077B (zh) * | 2020-06-02 | 2021-02-09 | 深圳市因诺赛生物科技有限公司 | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 |
CN112480268B (zh) * | 2020-12-10 | 2021-08-03 | 北京康乐卫士生物技术股份有限公司 | 一种新型冠状病毒的重组亚单位疫苗及其应用 |
-
2021
- 2021-04-09 HU HUE21720949A patent/HUE062716T2/hu unknown
- 2021-04-09 DK DK21720949.3T patent/DK3972987T3/da active
- 2021-04-09 LT LTEPPCT/US2021/026577T patent/LT3972987T/lt unknown
- 2021-04-09 HR HRP20230990TT patent/HRP20230990T1/hr unknown
- 2021-04-09 KR KR1020227039307A patent/KR20220167317A/ko unknown
- 2021-04-09 IL IL297064A patent/IL297064A/en unknown
- 2021-04-09 SI SI202130062T patent/SI3972987T1/sl unknown
- 2021-04-09 CN CN202180036445.3A patent/CN116096733A/zh active Pending
- 2021-04-09 JP JP2022561619A patent/JP2023522597A/ja active Pending
- 2021-04-09 US US17/226,690 patent/US11213581B2/en active Active
- 2021-04-09 AU AU2021253926A patent/AU2021253926B2/en active Active
- 2021-04-09 EP EP23176042.2A patent/EP4248983A3/en active Pending
- 2021-04-09 EP EP21720949.3A patent/EP3972987B1/en active Active
- 2021-04-09 FI FIEP21720949.3T patent/FI3972987T3/fi active
- 2021-04-09 WO PCT/US2021/026577 patent/WO2021207599A1/en unknown
- 2021-04-09 CA CA3146464A patent/CA3146464C/en active Active
- 2021-04-09 BR BR112022020486A patent/BR112022020486A2/pt unknown
- 2021-12-07 US US17/544,293 patent/US11707517B2/en active Active
-
2022
- 2022-09-12 AU AU2022231665A patent/AU2022231665B2/en active Active
- 2022-10-06 ZA ZA2022/10992A patent/ZA202210992B/en unknown
-
2023
- 2023-07-20 US US18/355,601 patent/US20240016921A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021253926B2 (en) | 2022-07-21 |
AU2022231665A1 (en) | 2022-10-06 |
EP3972987A1 (en) | 2022-03-30 |
CA3146464C (en) | 2024-03-12 |
HUE062716T2 (hu) | 2023-11-28 |
AU2021253926A1 (en) | 2022-02-24 |
IL297064A (en) | 2022-12-01 |
US20210346490A1 (en) | 2021-11-11 |
CA3146464A1 (en) | 2021-10-14 |
ZA202210992B (en) | 2023-08-30 |
SI3972987T1 (sl) | 2023-10-30 |
CN116096733A (zh) | 2023-05-09 |
US20220088182A1 (en) | 2022-03-24 |
HRP20230990T1 (hr) | 2023-12-08 |
US11213581B2 (en) | 2022-01-04 |
LT3972987T (lt) | 2023-09-25 |
EP4248983A2 (en) | 2023-09-27 |
WO2021207599A9 (en) | 2022-01-06 |
DK3972987T3 (da) | 2023-07-31 |
EP3972987B1 (en) | 2023-06-07 |
JP2023522597A (ja) | 2023-05-31 |
WO2021207599A1 (en) | 2021-10-14 |
EP4248983A3 (en) | 2024-01-24 |
FI3972987T3 (fi) | 2023-07-25 |
US11707517B2 (en) | 2023-07-25 |
US20240016921A1 (en) | 2024-01-18 |
KR20220167317A (ko) | 2022-12-20 |
AU2022231665B2 (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022020486A2 (pt) | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso | |
Fries et al. | A recombinant viruslike particle influenza A (H7N9) vaccine | |
Weldon et al. | Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity | |
BRPI0511776A (pt) | vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado | |
Abeck et al. | Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children | |
DK1644037T3 (da) | Funktionell infulenza-virus-lignende partikler (VLP'er) | |
ES2440974T3 (es) | Constructos poliepitópicos del VPH y uso de los mismos | |
CN1678344A (zh) | 人乳头状瘤病毒治疗 | |
Joyce et al. | Extended delivery of vaccines to the skin improves immune responses | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
JP6941566B2 (ja) | 固定化ウイルス粒子を含むワクチン | |
Christensen et al. | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis | |
BR0312474A (pt) | Partìcula viral adjuvante | |
BRPI0606165A2 (pt) | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada | |
Wang et al. | Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice | |
TW201601750A (zh) | 注射疫苗組合物 | |
Gilbert et al. | Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults≥ 50 years | |
Aricò et al. | Exploiting natural antiviral immunity for the control of pandemics: lessons from Covid-19 | |
JP6940649B2 (ja) | 皮内投与インフルエンザワクチン組成物 | |
WO2021156404A3 (en) | Treatment of hpv-related diseases | |
CN106535933B (zh) | 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物 | |
BR112022001070A2 (pt) | Composição de imunogenicidade polivalente para papilomavírus humano | |
Loebermann et al. | A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults | |
RU2290204C1 (ru) | Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани | |
Karuturi et al. | Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant |